Novartis settled with the family of Henrietta Lacks in 2026 for an undisclosed sum after using Lacks' cancerous cells in numerous patents decades after Lacks' cancerous cells were taken without her knowledge or consent.

The first line of 'immortal' human cells, which can divide indefinitely and are used in scientific research, was nonconsensually taken from a Black woman.

More than 100,000 scientific publications between 1953 and 2018 reported using HeLa cells—the cancerous cells nonconsensually taken from a Black woman named Henrietta Lacks in 1951.

'Immortal' HeLa cells—cancerous cells widely used in biomedical research after they were nonconsensually taken from a Black woman named Henrietta Lacks—proliferate easily, causing millions of dollars of damage annually by contaminating lab cell cultures.

60 years after seeing Henrietta Lacks as a patient, her doctor still remembered the unique cervical tumor that gave rise to the 'immortal' cell line now commonly used in biomedical research—it was purple, shiny, and soft—an appearance he said is very different from a typical tumor.

Henrietta Lacks' tumor cells became the first recognized 'immortal' cell line about 75 years ago, but researchers are still investigating the specific mechanisms that enabled the cells to continuously grow and divide in the laboratory.

Read an excerpt from 'The Immortal Life of Henrietta Lacks,' the story of the Black woman whose nonconsensually sampled cancerous cells underpin thousands of research papers and several Nobel Prize-winning works.

Scientists now know that Henrietta Lacks, a Black woman whose 'immortal' cancer cells were nonconsensually sampled and used for research, had been infected with human papillomavirus, a group of pathogens responsible for most cervical cancers.

See the trailer for the 2017 HBO movie 'The Immortal Life of Henrietta Lacks' starring Oprah Winfrey, who plays the daughter of the Black woman whose cancer cells were taken without her knowledge or permission, and now underpin numerous scientific discoveries.

This scientist treated her own cancer

Virologist Beata Halassy treated her own breast cancer by injecting the tumor with lab-grown viruses. Though this self-treatment worked, it has not been approved for widespread use. Read to learn more about her fascinating experience, and how it has led to conversations about safety and ethics.

HeLa cells, 'immortal' cancerous cells that continuously divide, were sent into space in 1960 on both Soviet and American missions—the samples were shared by American researchers as an example of scientific diplomacy amid the Cold War.

The spread of fraudulent stem cell treatments

All the coverage of research into promising (but often unproven) medical treatments involving stem cells has created conditions allowing some people to engage in activities regulators describe as scams. As this news article explains, attorneys general in at least seven states have taken legal action against businesses that promised (costly) stem cell treatments but allegedly engaged in fraud.

The first CRISPR-approved treatment was for sickle cell anemia in 2023

Victoria Gray was the first patient to receive a CRISPR-based therapy, which eliminated her symptoms and restored her health. The therapy's initial cost of $2.2M has kept it out of reach of many patients.

In 2023, at least 6 people were charged with stealing body parts

A recent case involving alleged trafficking in stolen human body parts charged that there was a nationwide network of individuals who bought and sold human remains. The charges alleged, among other things, that from 2018 through 2022, the manager of the morgue at Harvard Medical School's Anatomical Gifts Program stole organs and other parts of cadavers that had been donated for medical research and education. In late 2025, that Harvard morgue manager was sentenced to 96 months in prison.

In 2023, the FDA approved gene therapy for sickle cell disease, enabling one-time infusion bespoke treatments that use a patient's own stem cells to effectively cure a painful condition that disproportionately affects people of African American descent.

Hikma v. Amarin is a case the Supreme Court is hearing in 2026 that could impact how much you ultimately pay for prescription drugs

The case explores the liability of a generic drug maker for patent infringement. Hikma Pharmaceuticals launched a generic for Amarin Pharma's Vascepa (a fish oil drug), carving out a still-patented use and instead explicitly selling its product for another unprotected use. But Hikma was sued for its marketing materials that still alluded to the patented indication without outright referencing it.

Opioid epidemic 101: lawsuits and settlements

State and local governments trying to address the opioid epidemic have sued organizations they believe started and supported the crisis. Companies that made, distributed, or contributed to sales of the highly addictive painkillers are expected to pay more than $50B in settlements. These settlements specifically state that at least 85% of settlement funds must be spent on addressing the epidemic, though where exactly the money is going is unclear.

Following the NFL's concussion settlement, numerous victims were denied payouts

In 2015, the NFL finalized a landmark settlement with former players alleging concussions suffered in games were causing brain diseases. The settlement promised to pay every former player who developed dementia or diseases linked to concussions. This Washington Post investigation interviewed former players who filed claims under the agreement, but said they were rejected based on definitions in the settlement.

The US FDA considered mitochondrial replacement therapy during 2014 hearings

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

A man with organ failure used AI to speed discovery of his miracle drug

David Fajgenbaum had a few months to live after a diagnosis with a rare form of Castleman's disease. By studying his blood, medical records, and broader literature, he was able to identify the cause of his condition and a treatment. He's been in total relapse for ten years.

US federal researchers are blocked from putting certain human cells in animals

In 2015, US policymakers put a halt to any government-funded work that would insert human stem cells into animals. The reasoning was that human cells might spread through the animal's body and perhaps to its brain, blurring the line between humans and nonhumans. The ban remains in place today even as gene-edited pig parts are being placed in humans.

About 70% of the Human Genome Project's reference genome came from one donor

Volunteers who donated blood to the Human Genome Project consented to using no more than 10% of their DNA, raising questions about the project's legality. Listen to how pressure from a private competitor may have driven officials to ignore ethical standards.

How Gleevec transformed leukemia treatment and cancer research

An outline of the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginning of precision medicine.

A planned clinical trial to treat a rare lysosomal storage disorder in utero has buoyed hopes of providing prenatal gene therapies, but it was still awaiting FDA approval to begin enrolling patients as of May 2026.

The US FDA recently tried to regulate the expanded prenatal genetic tests

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.

A 2024 court ruling has had ripple effects for frozen embryos

The Alabama Supreme Court's 2024 ruling that embryos created through IVF are legally children has had a chilling effect on the fertility industry. A few centers for reproductive assistance paused egg fertilization, and others are questioning where the legal argument will lead. The decision has some surprising implications for the future of IVF technology, including techniques that haven't yet been invented.

In 2026, the FDA proposed a novel approach to expedite reviews of gene therapies for patients with rare genetic disorders such as cystic fibrosis, potentially bypassing the need for years-long clinical trials if approved.

23andMe declared bankruptcy in March 2025

The consumer genetic testing company, which offered detailed genetic profiles from users' saliva samples, suffered financially after they suffered a major data breach affecting almost 7 million customers in 2023. Its flagship product was a one-time genetic analysis which also made retention of users challenging.

How the Supreme Court established biotechnology patent law with an oil-eating microbe

While working at General Electric, microbiologist Ananda Chakrabarty engineered a strain of Pseudomonas that could break down multiple types of hydrocarbons and filed a patent on the bioremediation organism. Despite challenges over whether living things could be patented, the 5-4 decision held that genetically modified organisms could be patented because they were human-made inventions.

Former LuLaRoe vendors have accused the clothing multilevel marketing company of operating a pyramid scheme, resulting in more than 50 lawsuits and a $4.75M settlement.

The scandal that rocked stem cell research

In 2014, a Japanese research group published a paper suggesting ordinary cells could be reverted to pluripotent stem cells by subjecting them to external stressors. The results generated interest but could never be replicated. The lead researcher was accused of fraud, and the group’s supervisor committed suicide.

Implanted neurotechnology can leave users vulnerable when manufacturers go under

Despite providing relief from neurological conditions, patients are left stranded when the companies that make these devices shut down. The lack of regulation means patients often face technical failure, insurance battles, or risky surgeries to maintain their quality of life.

The Golden State killer case spotlights how genetic testing can affect your—and your relatives'—privacy

Police managed to use consumer DNA test results to close a case 32 years after a killer was believed to have committed at least 12 murders and 50 rapes. Their "smoking gun": They compared a DNA sample from the crime scene to genetic data relatives had shared on an open-source genealogy database. The suspect was caught after investigators explored family trees on this database and connected the dots from over 100 distant relatives who had some percentage of DNA that matched the killer. (Some users may encounter a paywall.)

Four frozen embryos in the US were created via 3-parent IVF technique

Columbia University researchers created four embryos using mitochondrial replacement therapy for four female patients who didn't want to pass on mitochondrial diseases to their children. Yet US law restricts the researchers from implanting the embryos so they remain frozen. (Some users may encounter a paywall.)

Read more about the backstory on the 2025 Nobel Prize for immune system work

A trio of scientists won the Nobel in Physiology or Medicine that year, but they performed their award-worthy work beginning about two decades before winning the prize. This announcement includes details about the science and notes that the three scientists will equally share the 11 million Swedish kronor (almost $1.2M).

How Nobel Prize-winning research unraveled why the immune system doesn't always attack itself

The 2025 Nobel Prize was awarded to scientists who discovered how immune system soldiers are typically stopped from attacking healthy tissue. The work furthered autoimmune understanding and cancer therapies.

The lack of diversity in DNA databases limits their applications

European ancestry dominates genetic research, hindering the usage of genetic databases for precision medicine for other groups, including African Americans, who face higher health risks due to genetic variants. Many Indigenous communities have also resisted genetic research due to past exploitation. (Some readers may experience a paywall.)

Early research suggests CAR-T therapy might treat scleroderma, reducing skin thickening

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

How two families navigated an unthinkable IVF mistake

The field offers hope to thousands of families annually, but it is also largely unregulated, and for a small number of parents, things can go terribly wrong.

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)